Cyxone AB announces promising T20K/KORa combination therapy efficacy in preclinical therapeutic model of MS
Cyxone AB (CYXO), a clinical-stage company developing transformative therapies in the autoimmune area to improve patient outcomes, today announced results from its ongoing collaboration with Medical University of Vienna.Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Cyxone and its research partner, the Medical University of Vienna, announced pre-clinical data further supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist (KORa). Previously Cyxone announced efficacy of